Introduction Modern biosimilar development increasingly depends on high-resolution structural and functional data as the principal surrogate for demonstrating therapeutic equivalence. […]
Introduction: Intact Mass Analysis and Middle-Up Characterization of Biosimilar mAbs are mass spectrometry-based approaches for evaluating the molecular identity and
Intact Mass Analysis and Middle-Up Characterisation Service for Biosimilar mAbs Read More »
Introduction The comprehensive implementation of Oral Peptide Drug Product Characterization requires an integrated assessment of intestinal permeation enhancers, enzymatic degradation
Introduction Characterizing Peptides in PLGA Microsphere and Depot Formulations requires sophisticated orthogonal analytical methodologies to assess complex drug release kinetics,
Introduction The Immunogenicity Risk Assessment of Peptide Impurities represents a critical regulatory evaluation framework established by the U.S. Food and
Immunogenicity Risk Assessment of Peptide Impurities in Generic Synthetic Peptide ANDAs Read More »
Introduction: An Insulin Glargine Biosimilar PK Comparability Study is a core part of the evidence showing that a proposed insulin
Introduction Assessing a Contract Development and Manufacturing Organization (CDMO) demands a systematic review of its technical capabilities, regulatory compliance, quality
What Questions Should You Ask a CDMO Before Signing a Contract? Read More »
Introduction CDMO services for Lipid Nanoparticle (LNP) Formulation and Characterization offer specialized contract development, scalable microfluidic manufacturing, and orthogonal analytical
Lipid Nanoparticle (LNP) Formulation and Characterization Services at a CDMO Read More »
Introduction CDMO Contract Models Explained: Contract Development and Manufacturing Organization (CDMO) contract models establish the legal, operational, and financial frameworks
CDMO Contract Models Explained: FTE, Fee-for-Service, and Milestone-Based Pricing Read More »
Introduction: Bioanalytical Method Development for Oligonucleotide Therapeutics is the process of building and validating a quantitative assay that measures an
